Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
famotidine histamine h2 receptor small molecule Successful target TTD , drugbank , DGIDB Disease Management[MeSHID:D019468]
Pathologic Processes[MeSHID:D010335]
Body Weight[MeSHID:D001835]
Diagnosis[MeSHID:D003933]
Heartburn[MeSHID:D006356]
Peptic Esophagitis[MeSHID:D004942]
Gastric ulcer[MeSHID:D013276]
Recurrence (disease attribute)[MeSHID:D012008]
Term Birth[MeSHID:D047929]
Zollinger-Ellison syndrome[MeSHID:D015043]
Esophagitis[MeSHID:D004941]
Multiple Endocrine Neoplasia[MeSHID:D009377]
Disease[MeSHID:D004194]
Duodenal Ulcer[MeSHID:D004381]
Gastritis[MeSHID:D005756]
Ulcer[MeSHID:D014456]
Urticaria[MeSHID:D014581]
Gastroesophageal reflux disease[MeSHID:D005764]
Risk Reduction[MeSHID:D040242]
Critical Illness[MeSHID:D016638]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Peptic Ulcer[MeSHID:D010437]		 10.4 approved antagonist
famotidine histamine h2 receptor small molecule Successful target TTD , drugbank , DGIDB Disease Management[MeSHID:D019468]
Pathologic Processes[MeSHID:D010335]
Body Weight[MeSHID:D001835]
Diagnosis[MeSHID:D003933]
Heartburn[MeSHID:D006356]
Peptic Esophagitis[MeSHID:D004942]
Gastric ulcer[MeSHID:D013276]
Recurrence (disease attribute)[MeSHID:D012008]
Term Birth[MeSHID:D047929]
Zollinger-Ellison syndrome[MeSHID:D015043]
Esophagitis[MeSHID:D004941]
Multiple Endocrine Neoplasia[MeSHID:D009377]
Disease[MeSHID:D004194]
Duodenal Ulcer[MeSHID:D004381]
Gastritis[MeSHID:D005756]
Ulcer[MeSHID:D014456]
Urticaria[MeSHID:D014581]
Gastroesophageal reflux disease[MeSHID:D005764]
Risk Reduction[MeSHID:D040242]
Critical Illness[MeSHID:D016638]
Coronavirus Infections[MeSHID:D018352]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]		 10.4 approved antagonist
click here to return to the previous page